Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders

Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the liter...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbasi-Afshar, R, Taheri, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shahid Sadoughi University of Medical Sciences 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921880/
https://www.ncbi.nlm.nih.gov/pubmed/24575284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921880/
https://www.ncbi.nlm.nih.gov/pubmed/24575284

Ejemplares similares